BR0101332A - Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80 - Google Patents

Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80

Info

Publication number
BR0101332A
BR0101332A BR0101332-7A BR0101332A BR0101332A BR 0101332 A BR0101332 A BR 0101332A BR 0101332 A BR0101332 A BR 0101332A BR 0101332 A BR0101332 A BR 0101332A
Authority
BR
Brazil
Prior art keywords
polysorbate
salts
cyclosporine
combination
aqueous solution
Prior art date
Application number
BR0101332-7A
Other languages
English (en)
Inventor
Guido Di Napoli
Original Assignee
Medidom Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medidom Lab filed Critical Medidom Lab
Publication of BR0101332A publication Critical patent/BR0101332A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO OFTáLMICA TóPICA NA FORMA DE UMA SOLUçãO AQUOSA, E, USO DE UMA CICLOSPORINA EM ASSOCIAçãO COM áCIDO HIALURÈNICO OU UM DE SEUS SAIS E COM POLISORBATO 80". Uma formulação oftálmica tópica na forma de uma solução aquosa compreendendo uma ciclosporina, ácido hialurónico ou um de seus sais, e polisorbato 80 é descrito.
BR0101332-7A 2000-04-07 2001-04-06 Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80 BR0101332A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH6942000 2000-04-07

Publications (1)

Publication Number Publication Date
BR0101332A true BR0101332A (pt) 2001-11-06

Family

ID=4529494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0101332-7A BR0101332A (pt) 2000-04-07 2001-04-06 Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80

Country Status (19)

Country Link
US (2) US6677304B2 (pt)
EP (1) EP1142566B1 (pt)
JP (1) JP2001316284A (pt)
CN (1) CN1185009C (pt)
AR (1) AR028291A1 (pt)
AT (1) ATE250924T1 (pt)
AU (1) AU778858B2 (pt)
BR (1) BR0101332A (pt)
CA (1) CA2342133C (pt)
CZ (1) CZ294385B6 (pt)
DE (1) DE60100866T2 (pt)
DK (1) DK1142566T3 (pt)
ES (1) ES2206363T3 (pt)
IL (1) IL142268A (pt)
PL (1) PL201055B1 (pt)
PT (1) PT1142566E (pt)
SK (1) SK285220B6 (pt)
TR (1) TR200302105T4 (pt)
ZA (1) ZA200102769B (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529934A (ja) * 2001-05-01 2004-09-30 アンジオテック ファーマシューティカルズ，インコーポレイテッド 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7326256B2 (en) 2002-12-06 2008-02-05 L'ORéAL S.A. Composition for the oxidation dyeing of keratin fibers, comprising at least one non-oxyalkenylated fatty alcohol, at least one oxidation dye, at least one associative polymer, and at least one amide of an alkanolamine and a C14-C30 fatty acid
FR2848106B1 (fr) * 2002-12-06 2006-11-17 Oreal Composition de teinture pour fibres keratiniques comprenant un alcool gras non oxyalkylene, un colorant d'oxydation, un polymere associatif et un amide d'une alcanolamine et d'un acide gras en c14-c30.
JP2004262777A (ja) * 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
WO2004096261A1 (es) * 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
DE602005011928D1 (de) * 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
WO2006067608A1 (en) * 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
CN100478025C (zh) * 2005-03-25 2009-04-15 中国科学院上海药物研究所 一种环孢菌素a眼用微乳制剂及其制备方法
AU2006265248B2 (en) * 2005-07-01 2011-12-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye-drops
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US20080306022A1 (en) * 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US20070212420A1 (en) * 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
EP2043628A4 (en) * 2006-06-27 2009-11-25 Riolan Technologies Inc ULTRAVIOLET ABSORBENT OPHTHALMIC COMPOSITIONS
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
WO2008119500A1 (en) * 2007-03-30 2008-10-09 Fovea Pharmaceuticals Sa Methods for treating neovascular ocular diseases
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
CN101820917B (zh) * 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
GB0904423D0 (en) * 2009-03-14 2009-04-29 Univ Strathclyde Improving the solubility of chemicals
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
EP2440185B1 (en) * 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013074610A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Sustained action formulation of cyclosporin form 2
US20130123194A1 (en) * 2011-11-15 2013-05-16 Allergan, Inc. Autoclavable suspensions of cyclosporin a form 2
FR2988297B1 (fr) * 2012-03-22 2014-03-28 Thea Lab Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
ES2837626T3 (es) 2013-07-10 2021-07-01 Matrix Biology Inst Composiciones de hialuronano con alta elasticidad y usos de las mismas
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
RU2713953C2 (ru) * 2014-07-18 2020-02-11 Аллерган, Инк. Суспензионные составы циклоспорина а для субконъюнктивального и периокулярного введения
ES2871199T3 (es) 2015-09-24 2021-10-28 Matrix Biology Inst Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas
KR101635915B1 (ko) * 2016-02-15 2016-07-04 삼천당제약주식회사 사이클로스포린과 히알루론산 또는 이의 염을 포함하는 수용액 형태의 안과용 조성물
EP3871682A1 (en) * 2016-10-14 2021-09-01 i.com Medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
JP2021530253A (ja) * 2018-03-29 2021-11-11 マティ セラピューティクス，インク． 眼科用徐放性製剤およびドライアイ症候群治療のための使用
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
KR20210141448A (ko) 2018-12-27 2021-11-23 서피스 아프샐믹스 인코포레이티드 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법
WO2021008668A1 (en) 2019-07-12 2021-01-21 Pharmathen S.A. Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
EP3988122A4 (en) * 2019-12-17 2023-01-18 Yizhou (Shanghai) Biological Medicine Co, Ltd. USE OF TRANSTHYRETIN FOR INTRODUCTION TO THE EYE AND MAKING DROPS
WO2021194948A1 (en) * 2020-03-23 2021-09-30 Eyegate Pharmaceuticals, Inc. Compositions and methods for treatment of ocular conditions
GR1010012B (el) 2020-05-12 2021-05-27 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
US11510930B2 (en) * 2020-08-26 2022-11-29 Somerset Therapeutics, Llc Gatifloxacin, prednisolone, and bromfenac compositions and methods
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2024019127A1 (ja) * 2022-07-20 2024-01-25 旭化成株式会社 ヒアルロン酸誘導体医薬組成物及び医薬組成物の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US592048A (en) * 1897-10-19 Drill-press
KR920003601B1 (ko) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤
HK1004520A1 (en) * 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
DK0756489T3 (da) * 1994-06-01 1999-12-06 Yuhan Corp Cyclosporinholdigt præparat og fremgangsmåde til fremstillingen af dette
JPH1160505A (ja) * 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd 防腐組成物

Also Published As

Publication number Publication date
EP1142566B1 (fr) 2003-10-01
CZ20011229A3 (cs) 2001-11-14
DE60100866D1 (de) 2003-11-06
US20040106546A1 (en) 2004-06-03
PT1142566E (pt) 2004-02-27
CN1185009C (zh) 2005-01-19
ATE250924T1 (de) 2003-10-15
US6677304B2 (en) 2004-01-13
CA2342133C (en) 2011-02-01
AR028291A1 (es) 2003-04-30
SK4602001A3 (en) 2001-11-06
DE60100866T2 (de) 2004-07-29
PL346926A1 (en) 2001-10-08
JP2001316284A (ja) 2001-11-13
ZA200102769B (en) 2001-10-05
DK1142566T3 (da) 2004-02-09
CA2342133A1 (en) 2001-10-07
US6953776B2 (en) 2005-10-11
CZ294385B6 (cs) 2004-12-15
IL142268A0 (en) 2002-03-10
PL201055B1 (pl) 2009-03-31
SK285220B6 (sk) 2006-09-07
EP1142566A1 (fr) 2001-10-10
TR200302105T4 (tr) 2004-02-23
AU778858B2 (en) 2004-12-23
IL142268A (en) 2007-08-19
ES2206363T3 (es) 2004-05-16
US20010041671A1 (en) 2001-11-15
AU3340401A (en) 2001-10-11
CN1317342A (zh) 2001-10-17

Similar Documents

Publication Publication Date Title
BR0101332A (pt) Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
CO5190689A1 (es) Sales de tramadol formadas por tramadol y un edulcorante y formas farmaceuticas que contienen dichas sales
BR9815609A (pt) Artigo absorvente com uma abertura para fezes na camada superior
BRPI0407723A (pt) artigo absorvente com gravação em relevo ao longo do perìmetro
BR0113751A (pt) Composições cosméticas e farmacêuticas e seus empregos
ES2111547T3 (es) Comprimido de liberacion prolongada.
BR0210013A (pt) Gel oftálmico de pirenzepina
BR0212031A (pt) Preparados de combinação de derivados de 1,1-dióxido de 1-4-benzotiepina com outras substâncias ativas e seu emprego
ATE248187T1 (de) Echinocandin-kohlenhydrate-komplexe
BR0005824A (pt) Sais de alquilespiroborato para uso em células eletroquìmicas
BR9801056A (pt) Auxiliadora de lavagem para utensílios de plásticos
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
DE69932860D1 (de) Verwendung von l-carnitin und seinen alkanoyl-derivaten als osmotisches mittel in lösungen für medizinische verwendung
DE60237847D1 (de) Saugfähiger artikel mit verbessertem sitz
DK1189595T3 (da) Ophthalmiske sammensætninger i form af vandige geler
TR200401363T4 (tr) DNA viral enfeksiyonlarının tedavisi
MY143099A (en) Novel skin care formulation
BR0014498A (pt) Artigos elásticos e uso dos mesmos
BR0010150A (pt) Solução oral de prucalopride
DK0973505T3 (da) Vandigt farmaceutisk præparat, der omfatter en aktiv ingrediens, som er meget tungt opløselig i vand
BR0107471A (pt) Airbag em formato de polìgono de doze lados
BR0010499A (pt) Agentes endoparasiticidas
DE50005076D1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
PT1007052E (pt) Combinacoes de progestinas de crescimento do endometrico e progestinas de atropia do endometrio com estrogenios, em contracepcao oral

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time